First genetic test for blindness

Saving the eyes of the next generation

Next time you head to the eye doctor, you might be sticking out your tongue.

MaRS incubator tenant Arctic Dx Inc. just announced a saliva-based genetic test — now available from your eye-care professional — that’s designed to determine your inherited risk for age-related macular degeneration (AMD), the leading cause of blindness in the western world.

75 to 80% of all AMD has been traced to genes inherited from family members. Until recently, there was no opportunity to determine who may carry these genes or be at risk. Knowing the risk and accessing appropriate care may save the vision of countless individuals who otherwise would not have taken necessary action until it was too late.

ArcticDx will introduce the test in Canada through the company’s exclusive Canadian distribution partner, Clarion Medical Technologies of Cambridge, Ontario.

To read more, check out the press release: Revolutionary Genetic Test Now Available For Age-Related Macular Degeneration.

Related Blogs

 

ArcticDX licenses genes for cancer test
An international team of researchers in colorectal cancer published the results of a study that links specific genes to the risk of colorectal cancer in this week’s Nature Genetics. Together, t

Arctic is heating up
Life Sciences Ontario (LSO) has appointed long-time MaRS client ArcticDX the 2012 Emerging Life Sciences Company of the Year. ArcticDX is a molecular diagnostic company that is commercializing progno

One step closer to better chemo for cancer
Congratulations to MaRS client RNA Diagnostics Inc., winners of the 2010 sanofi pasteur Healthcare and Biotechnology Venture Challenge (HBVC)! Rna Diagnostics’ product target is called RNA Disr

More funding to fight cancer
Cancer is the leading cause of death in Canada. In 2007, cancer accounted for almost 70,000 deaths across the country–more than heart disease and stroke combined. It’s rare to meet a pers

Closer to finding a cure to cancer/New target for cancer therapies
This week, exciting findings outlining a new target for cancer therapies was published in Nature by two independent groups, one in Toronto and one in Italy. They found that the real engines driving

Dx2010: Markers to markets
What’s the future of genetic diagnostics? Where do the commercialization opportunities exist? Now we know. On June 22, the Ontario Genomics Institute and MaRS Future of MedicineTM jointly held

Tags: arcticdx, diagnostics, health care, life sciences